Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX : NASDAQ)
Common Stock
$18.08
USD
+0.00 (%)
Last updated: 2026-09-17
Get AMRX alerts:
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
WealthAwesomePerformance
1 Day
+8.59%
1 Week
+4.81%
1 Month
-1.85%
YTD
+11.06%
Key Statistics
Market Cap
$6.30B
52W High
$19.26
52W Low
$9.49
P/E Ratio
34.77
50 Day MA
$17.75
200 Day MA
$14.53
Beta
1.24
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $18.56 | $19.18 | $18.12 | $18.28 | $18.28 | 2,816,756 |
| 9/16/2026 | $16.65 | $18.30 | $16.56 | $18.08 | $18.08 | 5,124,041 |
| 9/15/2026 | $17.22 | $17.25 | $16.58 | $16.65 | $16.65 | 1,793,400 |
| 9/14/2026 | $17.11 | $17.30 | $16.98 | $17.22 | $17.22 | 1,596,900 |
| 9/11/2026 | $17.00 | $17.11 | $16.73 | $17.01 | $17.01 | 1,157,600 |
| 9/10/2026 | $17.22 | $17.31 | $16.82 | $16.87 | $16.87 | 1,036,000 |
| 9/9/2026 | $17.27 | $17.36 | $17.08 | $17.25 | $17.25 | 1,472,300 |
| 9/8/2026 | $17.27 | $17.39 | $16.98 | $17.05 | $17.05 | 2,040,100 |
| 9/4/2026 | $17.57 | $17.70 | $17.37 | $17.44 | $17.44 | 1,440,900 |
| 9/3/2026 | $18.25 | $18.26 | $17.73 | $17.87 | $17.87 | 2,753,400 |
Analyst Price Targets
Based on 4 analysts covering AMRX · as of Sep 17, 2026
Wall Street analysts forecast AMRX stock price to rise 18.0% over the next 12 months.
Consensus
Buy4.25 / 5.00
Avg. Target
US$21.33
+18.0% Upside
Current Price
US$18.08
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMRX's historical volatility
30-Day Vol
40.4%
Annualized
90-Day Vol
36.2%
Annualized
Trend (90d)
+39.0%
Annualized drift
90d Mean
US$21.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$19.15 | US$16.66 – US$22.01 |
| 60 trading days | US$20.06 | US$16.47 – US$24.42 |
| 90 trading days | US$21.01 | US$16.51 – US$26.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Financials
- Revenue (TTM)
- $3.12B
- EBITDA
- $689.44M
- Profit Margin
- 5.05%
- ROE (TTM)
- 61.30%
- EPS (Diluted)
- 0.52
- Book Value
- 0.10
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About AMRX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |
AMRX.US news timeline
1 article covering AMRX.US, most recent first
Latest